Myelodysplastic Disorders

3

Review clinical trials related to Myelodysplastic Disorders. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.

Participants needed: 250
Trial details
Age: 1+Biological sex: AllType: InterventionalSponsor: Azienda Ospedaliero-Universitaria di ParmaUpdated: Mar 3, 2026Locations: 1
Eligibility criteria

Patient aged >1 year old, referred for evaluation to the University Hospital of... [+3]

Age <1 year old [+1]

Status: Recruiting

Feasibility of a Multi-omics Platform for Hematological Malignancies

This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.

Participants needed: 1,040
Trial details
Age: 2+Biological sex: AllType: InterventionalSponsor: Azienda Ospedaliero-Universitaria di ParmaUpdated: Mar 3, 2026Locations: 1
Eligibility criteria

Patient aged > 2 year old [+4]

Age <2 year old [+1]

Status: Recruiting

INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)

This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.

Participants needed: 300
Trial details
Age: 1+Biological sex: AllType: InterventionalSponsor: Azienda Ospedaliero-Universitaria di ParmaUpdated: Feb 17, 2026Locations: 2
Eligibility criteria

Patients aged one year and over who are referred to the centres involved in the... [+3]

Patients younger than 1 year old [+1]